NO306655B1 - Anvendelse av GLA, DGLA eller LA ved fremstilling av et medisinsk preparat - Google Patents

Anvendelse av GLA, DGLA eller LA ved fremstilling av et medisinsk preparat

Info

Publication number
NO306655B1
NO306655B1 NO932983A NO932983A NO306655B1 NO 306655 B1 NO306655 B1 NO 306655B1 NO 932983 A NO932983 A NO 932983A NO 932983 A NO932983 A NO 932983A NO 306655 B1 NO306655 B1 NO 306655B1
Authority
NO
Norway
Prior art keywords
preparation
dgla
gla
medical
efa
Prior art date
Application number
NO932983A
Other languages
English (en)
Norwegian (no)
Other versions
NO932983L (no
NO932983D0 (no
Inventor
David Frederick Horrobin
Brenda Elizabeth Reynolds
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of NO932983D0 publication Critical patent/NO932983D0/no
Publication of NO932983L publication Critical patent/NO932983L/no
Publication of NO306655B1 publication Critical patent/NO306655B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fertilizers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO932983A 1992-08-21 1993-08-20 Anvendelse av GLA, DGLA eller LA ved fremstilling av et medisinsk preparat NO306655B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929217780A GB9217780D0 (en) 1992-08-21 1992-08-21 Fatty acid treatment

Publications (3)

Publication Number Publication Date
NO932983D0 NO932983D0 (no) 1993-08-20
NO932983L NO932983L (no) 1994-02-22
NO306655B1 true NO306655B1 (no) 1999-12-06

Family

ID=10720716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932983A NO306655B1 (no) 1992-08-21 1993-08-20 Anvendelse av GLA, DGLA eller LA ved fremstilling av et medisinsk preparat

Country Status (20)

Country Link
US (1) US5618558A (https=)
EP (1) EP0585026B1 (https=)
JP (1) JPH06157303A (https=)
KR (1) KR940003553A (https=)
CN (1) CN1049334C (https=)
AT (1) ATE159856T1 (https=)
AU (1) AU666747B2 (https=)
CA (1) CA2104567A1 (https=)
DE (1) DE69315020T2 (https=)
DK (1) DK0585026T3 (https=)
ES (1) ES2110060T3 (https=)
GB (1) GB9217780D0 (https=)
GR (1) GR3025898T3 (https=)
MY (1) MY109928A (https=)
NO (1) NO306655B1 (https=)
NZ (1) NZ248422A (https=)
RU (1) RU2122409C1 (https=)
SG (1) SG80536A1 (https=)
TW (1) TW323230B (https=)
ZA (1) ZA935976B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
AU8857298A (en) * 1997-07-16 1999-02-10 Societe Des Produits Nestle S.A. Method for prophylaxis or treatment of bone density loss
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
EG22407A (en) 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
WO2002074308A1 (en) * 2001-03-15 2002-09-26 Roche Vitamins Ag Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
CA2442692A1 (en) * 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Bone metabolism improving agents
US7098352B2 (en) * 2001-11-16 2006-08-29 Virtus Nutrition Llc Calcium salt saponification of polyunsaturated oils
US20070105954A1 (en) * 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
EA200602014A1 (ru) * 2004-04-30 2007-08-31 ВИРТУС НЬЮТРИШН ЭлЭлСи Синтез солей одновалентных и двухвалентных металлов полиненасыщенных жирных кислот
CA2625338A1 (en) * 2005-10-07 2007-06-14 Ocean Nutrition Canada Ltd. Salts of fatty acids and methods of making and using thereof
DE102007022694A1 (de) * 2007-05-11 2008-11-13 Humana Milchunion Eg Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme
DE102007039310A1 (de) * 2007-08-13 2009-02-19 Eberhard-Karls-Universität Tübingen Universitätsklinikum Zusammensetzung zur Prophylaxe und Behandlung von Osteoporose
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
SI2395991T1 (sl) 2009-02-10 2013-12-31 Amarin Pharmaceuticals Ireland Limited Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011109724A1 (en) * 2010-03-04 2011-09-09 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
US8178707B2 (en) 2010-03-25 2012-05-15 Jost Chemical Company Co-precipitated salts of fatty acids
CN101978949A (zh) * 2010-11-16 2011-02-23 王京南 γ-亚麻酸酯脂肪乳静脉注射液及其制造方法
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
ES2784240T3 (es) 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
BR112018073060A2 (pt) * 2016-06-01 2019-04-09 Nestec S.A. composição para uso na profilaxia de doença alérgica
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417119A (en) * 1972-11-30 1975-12-10 Thiele G H Process for treating bones
GB8621816D0 (en) * 1986-09-10 1986-10-15 Efamol Ltd Therapeutic composition
JPH0625057B2 (ja) * 1987-12-14 1994-04-06 日本油脂株式会社 骨形成促進剤
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment

Also Published As

Publication number Publication date
JPH06157303A (ja) 1994-06-03
DK0585026T3 (da) 1998-06-02
ES2110060T3 (es) 1998-02-01
GR3025898T3 (en) 1998-04-30
SG80536A1 (en) 2001-05-22
DE69315020D1 (de) 1997-12-11
EP0585026A1 (en) 1994-03-02
CN1049334C (zh) 2000-02-16
NO932983L (no) 1994-02-22
NZ248422A (en) 1997-06-24
EP0585026B1 (en) 1997-11-05
CN1091285A (zh) 1994-08-31
RU2122409C1 (ru) 1998-11-27
ZA935976B (en) 1994-03-14
KR940003553A (ko) 1994-03-12
TW323230B (https=) 1997-12-21
AU4466693A (en) 1994-02-24
US5618558A (en) 1997-04-08
MY109928A (en) 1997-09-30
GB9217780D0 (en) 1992-10-07
HK1000997A1 (en) 1998-05-15
NO932983D0 (no) 1993-08-20
AU666747B2 (en) 1996-02-22
ATE159856T1 (de) 1997-11-15
DE69315020T2 (de) 1998-04-16
CA2104567A1 (en) 1994-02-22

Similar Documents

Publication Publication Date Title
NO306655B1 (no) Anvendelse av GLA, DGLA eller LA ved fremstilling av et medisinsk preparat
RU93049153A (ru) Лечение жирными кислотами
NL300224I1 (nl) 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl-of indanylalkyla-minoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen.
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
AU562938B2 (en) 7, 10, 13, 16 docosatetraenoic acid composition
DE59107331D1 (de) Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
CA2134479A1 (en) Laser treatment
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
WO1998025573A3 (en) The use of celastrol to treat alzheimer's disease
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
ES2053856T3 (es) Derivados del acido 4-quinoleino carboxilico utiles para el tratamiento de enfermedades de la piel y del muco-epitelio.
GR3006674T3 (https=)
ES2135500T3 (es) Producto farmaceutico para el tratamiento de trastornos de la piel.
BR9607996A (pt) Derivado de aminotetralina para o tratamento de doenças cardiovasculares
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2011472B3 (es) Procedimiento para el tratamiento de soluciones acuosas producidas en la carboxilacion de compuestos olefinicos no saturados.
RU95104302A (ru) Аппликационный материал лечебно-профилактического назначения
RU96113185A (ru) Раствор для лечения заболеваний и повреждений роговицы "кератан-с"
NO994930L (no) Preventiver og hjelpemidler for ulcerös kolitt og/eller Crohns sykdom
AU2716592A (en) Treatment of anxiety in benzodiazepine-withdrawn patients
DE69201975D1 (de) Pyrimido-benzothiazinderivate zur Behandlung von Entzündung, Allergie and kardiovaskulären Erkrankung.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN FEBRUARY 2002